It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Primary cells offer a more biologically relevant model than immortalized cell lines because they retain key functional features seen in vivo and avoid the mutations and genetic changes common in cell lines. With the rise of three-dimensional cultures, primary cells are becoming the gold standard for predictive assays.
Success in drug discovery depends on data that truly reflects human biology. That’s why we go beyond traditional cell lines to provide ethically sourced human and animal primary cells and tissues that enable you to make confident, clinically relevant decisions earlier in your program.
Our Capabilities
Wide range of cells and tissues: Healthy or diseased, human or animal, cryopreserved or freshly isolated.
Ethical & quality standards: All tissues are consented, quality-controlled, and processed in HTA-licensed facilities.
Rapid assessment Our in-house Blood Donor Panel delivers freshly isolated immune cells from arm to bench in as little as 30 minutes.
Customization: Bespoke in vitro assays tailored to replicate disease ex vivo and support screening cascades.
Our team bring extensive experience in isolation, handling, and assay design across multiple therapeutic areas. Capabilities include:
Access to diseased human cells for functional assays and mechanistic studies
Advanced blood-based assays with validated isolation methods
Flow cytometry and multi-parameter analysis
Why Choose Sygnature Discovery?
We combine physiologically relevant models with rapid turnaround and tailored solutions to deliver data you can trust. Our in-house blood donor panel ensures freshly isolated immune cells reach the bench within minutes, preserving viability and accuracy. Every sample is ethically sourced and quality-controlled in HTA-licensed facilities. By partnering with us, you gain access to bespoke assays and disease-relevant models that strengthen your screening cascades and accelerate your drug discovery journey.
Dive into the world of neuroinflammation research, featuring insights on in vitro models, in vivo testing, and stay updated with upcoming presentations at the Society for Neuroscience (SfN) event. Explore the latest in CNS drug discovery and innovation.
Blog
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
